Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 10/20 | 0.54 |
| ▸ | ATP4B | P51164 | 10/20 | 0.54 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.46 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.46 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.46 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.46 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.46 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.46 |
| ▸ | FXYD2 | P54710 | 4/20 | 0.46 |
| ▸ | ATP1A4 | Q13733 | 4/20 | 0.46 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9526802 | 0.91 | ATP4A (0.54) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL9837954 | 0.90 | ATP4A (0.44) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL10371426 | 0.90 | ATP4A (0.45) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL10371904 | 0.90 | ATP4A (0.45) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL23988295 | 0.90 | RUNX1 (0.51) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL23988286 | 0.90 | RUNX1 (0.51) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL6881053 | 0.90 | RUNX1 (0.51) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL13049572 | 0.90 | ATP4A (0.42) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL23988602 | 0.89 | ATP4A (0.41) | ATP4AATP4BATP1A1ATP1B1ATP1A3 | |
| SCHEMBL9835200 | 0.89 | ATP4A (0.41) | ATP4AATP4BATP1A1ATP1B1ATP1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| CN-104114169-A | Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis | ATOPIX THERAPEUTICS LTD | 2014-10-22 | — | — | CN | disclosed |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
| EP-0548103-A1 | USE OF PYRIDYLMETHYLSULPHINYL-1H-BENZIMIDAZOLE DERIVATES IN THE TREATMENT OF ILLNESSES CAUSED BY HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1993-06-30 | — | — | EP | disclosed |
| WO-1992004898-A1 | USE OF PYRIDYLMETHYLSULPHINYL-1H-BENZIMIDAZOLE DERIVATES IN THE TREATMENT OF ILLNESSES CAUSED BY HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1992-04-02 | — | — | WO | disclosed |
| EP-0166287-B1 | DIALKOXYRIDINES, PROCESS FOR THEIR PREPARATION, THEIR APPLICATION AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1989-08-23 | — | — | EP | disclosed |
| US-4758579-A | e.g. pantoprazole or pantoprazole sodium | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-07-19 | — | — | US | disclosed |
| EP-0166287-A1 | Dialkoxyridines, process for their preparation, their application and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | ATP4A 298/4885ATP4B 428/4885ATP1A1 318/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | ATP4A 1229/4885ATP4B 990/4885ATP1A1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.